FROM:
PR Newswire
June 28, 2001, Thursday 9:20 AM Eastern Time
SECTION: FINANCIAL NEWS
DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS
LENGTH: 581 words
HEADLINE: Neural & Stem Cell Therapies for Parkinson's Disease to be
Featured at Neurodegeneration Conference July 23-24 in Princeton, NJ
DATELINE: PRINCETON, N.J., June 28
BODY:
A featured paper at the "4th International Neurodegeneration in
Alzheimer's
Disease, Parkinson's Disease & Related Disorders" CONFERENCE on July
23-24 is entitled "The Evolution of Neural and Stem Cell Therapies for
Parkinson's
Disease." It will be presented by Dr. Ole Isacson of Harvard Medical
School and
McKlean Hospital, announces Strategic Research Institute.
This presentation will focus on "cell transfer, regeneration and
neurogenesis studies over the last 2 decades that have revolutionized
experimental neurology by demonstrations of a large capacity of the adult
mammalian brain for structural and functional plasticity. Systematic and
rigorous experiments have provided data and evidence for structural and
functional integration by transplanted fetal, and recently, stem-cell
derived
dopamine cells in animal models and patients with parkinsonism. Using
early and
basic techniques of cell implantation, this devastating disease may be
the first
to receive discernible benefits in patients. These developments are
likely to
be followed by major methodological advances in regeneration,
neurogenesis and
stem cell repair of the adult human brain."
To request a preliminary list of registered companies and academic
institutions, see contact information below.
Other papers featuring new work in the area of Parkinson's Disease
are to be
presented by Dr. Michael G. Schlossmacher of Brigham & Women's Hospital
and
Harvard Medical School, entitled "The Role of Parkin in
Synucleinopathies";
"Alpha-Synuclein and Parkinson's Disease" to be presented by Dr. Yasuji
Matsuoka of the New York University Medical Center and Nathan Kline
Institute; a the third paper to be presented by Dr. Anja Leona Biere of
Amgen, Inc., entitled
"Mechanistic Studies on a-, b- and g-Synuclein Aggregation and Vesicle
Binding,"
and "Drosophila Model of Parkinson's Disease" to be presented Dr. Mel B.
Feany,
of Brigham & Women's Hospital.
The broad-based meeting is divided into six sections, namely,
Pathophysiology of Alzheimer's Disease, Amyloid Processing, Novel
Therapeutic
Targets for Neurodegeneration, Parkinson's Disease, Novel Therapeutic
Targets in
Neurodegeneration, and Therapeutic Advances.
Other presenting companies and academic institutions include Aventis
Pharmaceuticals, NeoTherapeutics, The R.W. Johnson Pharmaceutical
Research
Institute, Binzou People's Hospital -- China, MitoKor, Neurochem,
University of
Pennsylvania School Of Medicine, Johns Hopkins University, Eli Lilly &
Company,
Exelexis, and ACADIA Pharmaceuticals, among others.
To request the agenda, please contact Sem Sepulveda at
ssepulveda@srinstitute or Bebe Anderson at [log in to unmask] or
212-967-0095, ext. 255. You may request a list of registered companies
and
academic institutions and exhibitors. Please include your affiliation
and
mailing address.
For information on the exposition and sponsorship opportunities i.e.
luncheons, the reception, or totebag or writing portfolio giveaways,
contact
Mark Alexay at [log in to unmask]
SOURCE Strategic Research Institute
CONTACT: Sem Sepulveda, ssepulveda@srinstitute, or Bebe Anderson,
212-967-0095, ext. 255, [log in to unmask], or Mark Alexay at
[log in to unmask], all for Strategic Research Institute
URL: http://www.prnewswire.com
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
